Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium
<b>Background:</b><i>Salmonella</i> Typhimurium is a major zoonotic pathogen, in which type 1 fimbriae play a crucial role in intestinal colonization and immune modulation. This study aimed to improve the protective immunity of a previously developed growth-deficient strain—a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/6/659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433908656996352 |
|---|---|
| author | Patricia García Arianna Rodríguez-Coello Andrea García-Pose María Del Carmen Fernández-López Andrea Muras Miriam Moscoso Alejandro Beceiro Germán Bou |
| author_facet | Patricia García Arianna Rodríguez-Coello Andrea García-Pose María Del Carmen Fernández-López Andrea Muras Miriam Moscoso Alejandro Beceiro Germán Bou |
| author_sort | Patricia García |
| collection | DOAJ |
| description | <b>Background:</b><i>Salmonella</i> Typhimurium is a major zoonotic pathogen, in which type 1 fimbriae play a crucial role in intestinal colonization and immune modulation. This study aimed to improve the protective immunity of a previously developed growth-deficient strain—a double auxotroph for D-glutamate and D-alanine—by engineering the inducible expression of type 1 fimbriae. <b>Methods</b>: P<i><sub>tetA</sub></i>-driven expression of the <i>fim</i> operon was achieved by λ-Red mutagenesis. <i>fimA</i> expression was quantified by qRT-PCR, and fimbriation visualized by transmission electron microscopy. Adhesive properties were evaluated through FimH sequence analysis, yeast agglutination, mannose-binding/inhibition assays, and HT-29 cell adherence. BALB/c mice were immunized orogastrically with IRTA ΔΔΔ or IRTA ΔΔΔ P<i><sub>tetA</sub></i>::<i>fim</i>. Safety and immunogenicity were assessed by clinical monitoring, bacterial load, fecal shedding, ELISA tests, and adhesion/blocking assays using fecal extracts. Protection was evaluated after challenging with wild-type and heterologous strains. <b>Results:</b> IRTA ΔΔΔ P<i><sub>tetA</sub></i>::<i>fim</i> showed robust <i>fimA</i> expression, dense fimbrial coverage, a marked mannose-sensitive adhesive phenotype and enhanced HT-29 attachment. Fimbrial overexpression did not alter intestinal colonization or translocation to mesenteric lymph nodes (mLNs). Immunization elicited a mixed IgG1/IgG2a, significantly increased IgA and IgG against type 1 fimbriae-expressing <i>Salmonella</i>, and enhanced the ability of fecal extracts to inhibit the adherence of wild-type strains. Upon challenge (IRTA wild-type/20220258), IRTA ΔΔΔ P<i><sub>tetA</sub></i>::<i>fim</i> reduced infection burden in the cecum (−1.46/1.47-log), large intestine (−1.35/2.17-log), mLNs (−1.32/0.98-log) and systemic organs more effectively than IRTA ΔΔΔ. <b>Conclusions</b>: Inducible expression of type 1 fimbriae enhances mucosal immunity and protection, supporting their inclusion in next-generation <i>Salmonella</i> vaccines. Future work should assess cross-protection and optimize FimH-mediated targeting for mucosal delivery. |
| format | Article |
| id | doaj-art-3fce773ae1dd4485af8a3f6280bee7e3 |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-3fce773ae1dd4485af8a3f6280bee7e32025-08-20T03:26:52ZengMDPI AGVaccines2076-393X2025-06-0113665910.3390/vaccines13060659Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> TyphimuriumPatricia García0Arianna Rodríguez-Coello1Andrea García-Pose2María Del Carmen Fernández-López3Andrea Muras4Miriam Moscoso5Alejandro Beceiro6Germán Bou7Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, SpainServicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, Spain<b>Background:</b><i>Salmonella</i> Typhimurium is a major zoonotic pathogen, in which type 1 fimbriae play a crucial role in intestinal colonization and immune modulation. This study aimed to improve the protective immunity of a previously developed growth-deficient strain—a double auxotroph for D-glutamate and D-alanine—by engineering the inducible expression of type 1 fimbriae. <b>Methods</b>: P<i><sub>tetA</sub></i>-driven expression of the <i>fim</i> operon was achieved by λ-Red mutagenesis. <i>fimA</i> expression was quantified by qRT-PCR, and fimbriation visualized by transmission electron microscopy. Adhesive properties were evaluated through FimH sequence analysis, yeast agglutination, mannose-binding/inhibition assays, and HT-29 cell adherence. BALB/c mice were immunized orogastrically with IRTA ΔΔΔ or IRTA ΔΔΔ P<i><sub>tetA</sub></i>::<i>fim</i>. Safety and immunogenicity were assessed by clinical monitoring, bacterial load, fecal shedding, ELISA tests, and adhesion/blocking assays using fecal extracts. Protection was evaluated after challenging with wild-type and heterologous strains. <b>Results:</b> IRTA ΔΔΔ P<i><sub>tetA</sub></i>::<i>fim</i> showed robust <i>fimA</i> expression, dense fimbrial coverage, a marked mannose-sensitive adhesive phenotype and enhanced HT-29 attachment. Fimbrial overexpression did not alter intestinal colonization or translocation to mesenteric lymph nodes (mLNs). Immunization elicited a mixed IgG1/IgG2a, significantly increased IgA and IgG against type 1 fimbriae-expressing <i>Salmonella</i>, and enhanced the ability of fecal extracts to inhibit the adherence of wild-type strains. Upon challenge (IRTA wild-type/20220258), IRTA ΔΔΔ P<i><sub>tetA</sub></i>::<i>fim</i> reduced infection burden in the cecum (−1.46/1.47-log), large intestine (−1.35/2.17-log), mLNs (−1.32/0.98-log) and systemic organs more effectively than IRTA ΔΔΔ. <b>Conclusions</b>: Inducible expression of type 1 fimbriae enhances mucosal immunity and protection, supporting their inclusion in next-generation <i>Salmonella</i> vaccines. Future work should assess cross-protection and optimize FimH-mediated targeting for mucosal delivery.https://www.mdpi.com/2076-393X/13/6/659live auxotrophic vaccinestype 1 fimbriaeFimHmucosal vaccinefecal IgA<i>Salmonella</i> Typhimurium |
| spellingShingle | Patricia García Arianna Rodríguez-Coello Andrea García-Pose María Del Carmen Fernández-López Andrea Muras Miriam Moscoso Alejandro Beceiro Germán Bou Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium Vaccines live auxotrophic vaccines type 1 fimbriae FimH mucosal vaccine fecal IgA <i>Salmonella</i> Typhimurium |
| title | Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium |
| title_full | Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium |
| title_fullStr | Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium |
| title_full_unstemmed | Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium |
| title_short | Engineering and Evaluation of a Live-Attenuated Vaccine Candidate with Enhanced Type 1 Fimbriae Expression to Optimize Protection Against <i>Salmonella</i> Typhimurium |
| title_sort | engineering and evaluation of a live attenuated vaccine candidate with enhanced type 1 fimbriae expression to optimize protection against i salmonella i typhimurium |
| topic | live auxotrophic vaccines type 1 fimbriae FimH mucosal vaccine fecal IgA <i>Salmonella</i> Typhimurium |
| url | https://www.mdpi.com/2076-393X/13/6/659 |
| work_keys_str_mv | AT patriciagarcia engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT ariannarodriguezcoello engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT andreagarciapose engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT mariadelcarmenfernandezlopez engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT andreamuras engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT miriammoscoso engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT alejandrobeceiro engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium AT germanbou engineeringandevaluationofaliveattenuatedvaccinecandidatewithenhancedtype1fimbriaeexpressiontooptimizeprotectionagainstisalmonellaityphimurium |